Results 51 to 60 of about 6,042 (221)

Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice

Медицинский совет, 2022
Psoriasis is an immune-mediated, chronic inflammatory skin disease, which is currently regarded as a systemic process given its association with multiple comorbid conditions. In psoriasis, there is a complex interaction between T cells and keratinocytes.
O. V. Zhukova, S. I. Artemyeva
doaj   +1 more source

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]

, 2019
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of
Lee, Erica B, Liao, Wilson, Pithadia, Deeti J, Reynolds, Kelly A, Wu, Jashin J   +4 more
core  

Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]

, 2015
The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core   +3 more sources

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial [PDF]

, 2022
Introduction: The phase 3 DISCOVER-2 trial evaluated the effect of guselkumab on impaired work productivity and nonwork activity in biologic-naïve patients with psoriatic arthritis (PsA).
Agarwal, Prasheen, Curtis, Jeffrey R, Gladman, Dafna D, Han, Chenglong, Hsia, Elizabeth C, Kollmeier, Alexa P, McInnes, Iain B, Mease, Philip J, Peterson, Steven, Rahman, Proton, Shawi, May, Shiff, Natalie J, Tillett, William, Yang, Feifei, Zhou, Bei   +14 more
core   +2 more sources

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Mesenchymal Stromal Cells and Their Extracellular Vesicles Enhance the Anti-Inflammatory Phenotype of Regulatory Macrophages by Downregulating the Production of Interleukin (IL)-23 and IL-22 [PDF]

, 2018
Resolution-phase macrophage population orchestrates active dampening of the inflammation by secreting anti-inflammatory and proresolving products including interleukin (IL)-10 and lipid mediators (LMs).
Holopainen, Minna, Hyvärinen, Kati, Kerkelä, Erja, Korhonen, Matti, Käkelä, Reijo, Laitinen, Saara, Lehenkari, Petri, Ruhanen, Hanna, Skirdenko, Vita   +8 more
core   +2 more sources

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

Arthritis Research & Therapy, 2021
Background The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue.
Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han   +12 more
doaj   +1 more source

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M, Liao, Wilson, Sanchez, Isabelle M, Yang, Eric J   +3 more
core  

Autoimmunity and COPD: clinical implications. [PDF]

, 2017
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries.
Amatya, Antonino Di Stefano, Barnes, Blum, Born, Caramori, Cheng, Cooper, Cosio, Cosio, Craig, Daffa, Di Stefano, Di Stefano, Durham, Dörner, Eich, Feghali-Bostwick, Gaetano Caramori, Ganusov, Ghosh, Giuseppe Girbino, Guerreiro Castro, Hennes, Hodge, Hodge, Hoe, Hogg, Ian M. Adcock, John-Schuster, Kanoh, Kirkham, Korn, Kuhn, Kunz, Kurschus, Lee, Lobo, Luo, Moreno Torres, Morissette, Motz, Motz, Ni, Núñez, Paolo Ruggeri, Paul Kirkham, Pitzalis, Polverino, Roos, Schroeder, Seys, Sharon Mumby, Steri, Sullivan, Westermann, Wong, Xiong, Yadava   +58 more
core   +1 more source